1. Prolonged efavirenz exposure reduces peripheral oxytocin and vasopressin comparable to known drugs of addiction in male Sprague Dawley rats
- Author
-
Brian H. Harvey, Mandi Le Roux, and Marisa Möller
- Subjects
M, muscarinic ,Vasopressin ,ARRIVE, animal research: reporting of in vivo experiments (guidelines) ,PND, postnatal day ,Pharmacology ,Oxytocin ,Methamphetamine ,SD, Sprague Dawley (rat) ,chemistry.chemical_compound ,Cocaine ,DAT, dopamine transporter ,cART, combined antiretroviral therapy ,CPP, conditioned place preference ,EFV, efavirenz ,NAc, nucleus accumbens ,media_common ,HNS, hypothalamic neurohypophysial system ,OT, oxytocin ,General Neuroscience ,NPAE, neuropsychiatric adverse effect ,VPR, vasopressin receptor ,ELISA, enzyme-linked immunosorbent assay ,HPA, hypothalamic-pituitary-adrenal (axis) ,ANOVA, one-way analysis of variance ,CB, cannabinoid ,HIV, human immunodeficiency virus ,SON, supraoptic nucleus ,ARV, antiretroviral ,DOA‘s, drug(s) of abuse ,OTR, oxytocin receptor ,ADH, antidiuretic hormone ,IP, intraperitoneal ,IV, intravenous ,VP, vasopressin ,RC321-571 ,Research Paper ,medicine.drug ,Ach, acetylcholine ,MAO, monoamine oxidase ,Drug ,Efavirenz ,media_common.quotation_subject ,Neurosciences. Biological psychiatry. Neuropsychiatry ,Context (language use) ,∆9-THC, delta-9-tetrahydrocannabinol ,CNS, central nervous system ,SEM, standard error of the mean ,SERT, serotonin transporter ,medicine ,AEA, N-arachidonoylethanolamine (anandamide) ,Adverse effect ,∆9-tetrahydrocannabinol ,NO, nitric oxide ,Glu, glutamate ,business.industry ,SC, subcutaneous ,MA, methamphetamine ,chemistry ,GABA, gamma-aminobutyric acid ,DA, dopamine ,VMAT, vesicular monoamine transporter ,business ,5-HT, 5-hydroxytryptamine (serotonin) ,NE, norepinephrine ,ECS, endocannabinoid system ,PVN, paraventricular nucleus ,Hormone - Abstract
Introduction Several drugs of abuse (DOA) are capable of modulating neurohypophysial hormones, such as oxytocin (OT) and vasopressin (VP), potentially resulting in the development of psychological abnormalities, such as cognitive dysfunction, psychoses, and affective disorders. Efavirenz (EFV), widely used in Africa and globally to treat HIV, induces diverse neuropsychiatric side effects while its abuse has become a global concern. The actions of EFV may involve neurohypophysial system (NS) disruption like that of known DOA. This study investigated whether sub-chronic EFV exposure, at a previously-determined rewarding dose, alters peripheral OT and VP levels versus that of a control, ∆9-tetrahydrocannabinol (∆9-THC), methamphetamine (MA) and cocaine. Materials and methods To simulate the conditions under which reward-driven behavior had previously been established for EFV, male Sprague Dawley rats (n = 16/exposure) received intraperitoneal vehicle (control) or drug administration across an alternating sixteen-day dosing protocol. Control administration (saline/olive oil; 0.2 ml) occurred on odd-numbered and drug administration (EFV: 5 mg/kg, ∆9-THC: 0.75 mg/kg, MA: 1 mg/kg, or cocaine: 20 mg/kg) on even-numbered days followed by euthanasia, trunk blood collection and plasma extraction for neuropeptide assay. Effect of drug exposure on peripheral OT and VP levels was assessed versus controls and quantified using specific ELISA kits. Statistical significance was determined by Kruskal-Wallis ANOVA, with p, Highlights • Efavirenz alters rat plasma neuropeptide levels in a similar manner to illicit drugs. • Opposed to cocaine, methamphetamine reduces plasma vasopressin rather than oxytocin. • Efavirenz and ∆−9-tetrahydrocannabinol comparably affect peripheral neuropeptides. • Efavirenz reduces vasopressin more than oxytocin versus ∆−9-tetrahydrocannabinol.
- Published
- 2021
- Full Text
- View/download PDF